Skip to content
StackItSmart
DPreclinical / mechanistic only
No human data

PEG-MGF

Mechano Growth Factor

PEG-MGF (pegylated Mechano Growth Factor) is a synthetic, PEGylated peptide based on the C-terminal "E-domain" of IGF-1Ec, a mechanically- and injury-responsive splice variant of the IGF-1 gene. It is sold as an unregulated "research peptide" and injected by bodybuilders who believe it accelerates local muscle repair and hypertrophy after training. The single most important fact is that no peer-reviewed human studies of PEG-MGF exist: no clinical trials, no human pharmacokinetics, no human safety data, and no approved medical indication. Every claimed benefit derives from preclinical (cell-culture and animal) work on native MGF/E-domain peptides plus anecdotal internet reports. The main dangers are therefore (1) unknown, unstudied human toxicity, and (2) a biologically plausible but unproven mitogenic/oncogenic concern, because MGF (IGF-1Ec) signaling is implicated in cancer cell proliferation. Product identity, purity, dose, and contamination in the grey-market supply are also unknown. Evidence is graded D (preclinical/mechanistic only). Anyone using or considering PEG-MGF should understand they are self-experimenting with an unstudied drug and should involve a physician.

Clinical readoutPeptide · igf
Hepatic strainNone
CardiovascularNone
HPTA suppressionNone
Half-life
Not established i…
Route
No peer-reviewed human…
Evidence
D
Active
Unknown in humans
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not established in humans. No peer-reviewed human pharmacokinetic study of PEG-MGF has reported a half-life. PEGylation is intended to extend the native peptide's stability/persistence (native, non-pegylated MGF E-domain is cleared within minutes in preclinical settings), but the actual human half-life is unknown.
Pharmacology

Mechanism of action

PEG-MGF is a synthetic analog of the unique E-domain peptide produced by the IGF-1Ec (Mechano Growth Factor, MGF) splice variant of IGF-1. Native MGF is transcribed locally in skeletal muscle in response to mechanical loading and injury; a reading-frame shift during splicing gives it a distinct C-terminal E-peptide with a mode of action different from systemic/liver IGF-1, and it is thought to act as a local repair/regeneration signal rather than a systemic growth factor. Preclinically, the MGF E-peptide activates muscle satellite cells and myoblasts, increasing their proliferation and fusion potential and delaying terminal differentiation and senescence. It is generally described as acting through IGF-1 receptor (IGF-1R) tyrosine-kinase signaling and downstream somatomedin pathways, though some experimental work (e.g., cardiac cell models) shows the isolated E-domain can be taken up into cells and localize to the nucleus independently of IGF-1R activation. "PEG" refers to covalent attachment of polyethylene glycol, intended to slow degradation and prolong the very short in-vivo persistence of the native peptide. No human study has confirmed the mechanism, receptor engagement, or tissue distribution of the PEGylated product in people; the mechanism is inferred from preclinical MGF/E-domain biology.
Kinetics

Pharmacokinetics

Half-life

Not established in humans. No peer-reviewed human pharmacokinetic study of PEG-MGF has reported a half-life. PEGylation is intended to extend the native peptide's stability/persistence (native, non-pegylated MGF E-domain is cleared within minutes in preclinical settings), but the actual human half-life is unknown.

Active duration

Unknown in humans. Claimed prolonged local/systemic action from PEGylation is not supported by any human data; duration cannot be stated.

Route

No peer-reviewed human study has reported a route of administration. Grey-market/anecdotal use is subcutaneous or intramuscular injection. This monograph does not endorse self-injection; route information is for clinical/monitoring context only, not test evasion.

Metabolism & clearance

Not characterized in humans. As a peptide it is expected to undergo proteolytic/peptidase degradation to amino acid fragments with renal handling of the PEG moiety, but no human ADME data exist.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • No proven effects in humans: there are no peer-reviewed human efficacy or clinical outcome data for PEG-MGF.
  • Claimed effects (faster muscle recovery, satellite-cell activation, hypertrophy, improved body composition) are extrapolated from preclinical work on native MGF/E-domain peptides and remain unproven in people.
  • In cell culture, MGF/E-domain peptides increase proliferation and fusion of human muscle satellite cells/myoblasts and delay their terminal differentiation and senescence (in vitro only).
  • In animal and cell models, MGF E-domain peptides have shown tissue-repair effects (cartilage chondrocyte proliferation/matrix synthesis; preservation of cardiac function after experimental myocardial infarction). These are preclinical and do not establish any human benefit.
  • Internet-forum claims of 'local-only action' with no systemic effects are anecdotal and unverified; they cannot substitute for controlled safety or efficacy data.
Safety

Adverse effects by system

Cardiovascular

No human safety data. Preclinical models show MGF E-domain peptides can affect cardiac tissue (anti-apoptotic, function-preserving after infarction in mice), but this does not establish cardiovascular safety in humans and effects of chronic IGF-axis stimulation on the heart are unknown.

Hepatic

No human data. No evidence of direct hepatotoxicity; peptides of this class are not known liver toxins, but hepatic safety of PEG-MGF has never been studied in humans.

Endocrine / HPTA

No human data specific to PEG-MGF. As an IGF-1R-axis agent it could theoretically influence GH/IGF-1 feedback and glucose/insulin dynamics, but no measured endocrine effects (including on the hypothalamic-pituitary-gonadal axis) have been reported in humans.

Reproductive

No human data. Effects on fertility, pregnancy, or reproductive hormones are unstudied; use in pregnancy or breastfeeding is contraindicated by default given growth-factor mitogenic activity and absent safety data.

Neuropsychiatric

No known or reported psychiatric effects; no human data exist to characterize any neuropsychiatric risk.

Renal

No human data. Chronic IGF-1-axis stimulation is theoretically associated with renal hypertrophy/glomerular changes, and the PEG moiety is renally handled, but nothing has been studied for PEG-MGF in humans.

Hematologic

No known or reported hematologic effects; no human data available to characterize hematologic risk.

Dermatologic

No systematic human data. Injection-site reactions (pain, redness, swelling) are plausible with any injectable peptide and are reported anecdotally; sterility/contamination of grey-market product is an added infection risk.

Recovery

HPTA suppression & recovery

Suppression: Not established; no direct HPTA suppression documented for PEG-MGF in humans.

PEG-MGF is an IGF-1-axis peptide, not an androgen, so classic testosterone-axis suppression is not its expected primary effect, but there are no human data confirming its impact on the hypothalamic-pituitary-gonadal or GH/IGF-1 feedback axes. Any HPTA/endocrine concern should be evaluated with bloodwork and managed by an endocrinologist. If restoration of a suppressed axis is ever needed, that is a single-SERM decision made and supervised by a physician/endocrinologist; this monograph does not recommend any self-directed SERM protocol and never any dual-SERM regimen.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic clinician-ordered bloodwork before/if using: CBCComprehensive metabolic panel (glucose, renal and hepatic markers)Fasting glucose and HbA1cIGF-1 levelAge-appropriate cancer screening per a physicianPSA where age/sex-appropriate

Cadence: Establish a baseline with a clinician before any use; because no human data define a safe monitoring interval, defer cadence to a physician. A pragmatic approach is baseline, then reassessment at roughly 8-12 week intervals during any use and promptly if symptoms arise.

Warning signs — seek care
  • New or growing lumps/masses, unexplained weight loss, or other cancer red-flags - stop and seek urgent evaluation
  • Signs of hypoglycemia (shakiness, sweating, confusion)
  • Persistent injection-site infection (spreading redness, pus, fever)
  • New swelling/fluid retention, joint or muscle pain
  • Chest pain, palpitations, shortness of breath, or new edema
  • Any severe or unexpected symptom - stop use and consult a clinician
Do not use if

Contraindications

  • Active or prior cancer, or elevated cancer risk: IGF-1Ec/MGF signaling is implicated in tumor cell proliferation, a biologically plausible oncologic hazard for IGF-axis stimulation (theoretical, preclinical basis).
  • Pregnancy and breastfeeding (mitogenic growth factor; no safety data).
  • Children/adolescents and anyone with active growth-plate or growth-disorder concerns.
  • Diabetes or impaired glucose tolerance (theoretical IGF-1R-mediated effects on glucose/insulin dynamics; unstudied).
  • Any use without medical supervision, given the complete absence of human safety data and unregulated product quality.
  • Known hypersensitivity to the peptide or PEG.
Combinations

Interaction profile

  • ModerateWith an anabolic steroid: Additive cardiovascular strain
  • MajorWith insulin: Metabolic / glucose
  • ModerateWith growth hormone: Metabolic / glucose
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Understand the core fact: PEG-MGF has no human trials, no human pharmacokinetic or safety data, and no approved medical use - using it is self-experimentation with an unstudied drug.
  • Do not treat internet-forum claims of 'local-only, side-effect-free' action as evidence; they are anecdotal and unverifiable.
  • Because IGF-axis growth-factor signaling is linked to tumor proliferation in preclinical work, anyone with a personal or family cancer history should not use it and should discuss the theoretical oncologic risk with a physician.
  • If you use it despite the unknowns, involve a clinician: get baseline bloodwork (including IGF-1, glucose/HbA1c, CBC, metabolic panel) and age-appropriate cancer screening first.
  • Stop immediately and seek medical care for any new lump or mass, unexplained weight loss, signs of infection at an injection site (spreading redness, pus, fever), hypoglycemia, chest pain/palpitations, or significant swelling.
  • Never use during pregnancy or breastfeeding, in adolescents, or alongside active cancer.
  • Grey-market peptide products carry unknown identity, dose, purity, and contamination/sterility risks; there is no way to verify what is in a vial.
  • This is not medical advice; decisions about use, monitoring, and any endocrine follow-up should be made with a physician or endocrinologist.
Evidence

Citations (8)

Every clinical claim above is tied to a primary source. Overall evidence grade D — this compound lacks adequate human data; claims rest on preclinical or mechanistic evidence.

  1. 01

    PEG-MGF (pegylated mechano growth factor) is an IGF-1 analogue used off-label as a performance/physique 'research peptide' with no peer-reviewed human studies; it is assigned the lowest evidence tier (tier D), supported only by preclinical extrapolation and grey-literature user narratives.

    ReviewThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.PMID 42395176 ↗

  2. 02

    No peer-reviewed human studies of PEG-MGF have reported route of administration or half-life; PEGylation extends stability; mechanism is inferred as IGF-1R tyrosine-kinase signaling and satellite-cell proliferation from preclinical data; there is a theoretical proliferative/oncologic concern based on IGF-1Ec (MGF) expression in cancer biology.

    ReviewThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.PMID 42395176 ↗

  3. 03

    Reported PEG-MGF dosing regimens circulating among users are derived only from bodybuilding-forum anecdote, not from any clinical trial, underscoring the complete absence of validated human dosing data.

    ReviewThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.PMID 42395176 ↗

  4. 04

    MGF is a muscle-specific splice variant of the IGF-1 gene whose E-domain and reading-frame shift give it a distinct C-terminal peptide and a local repair/regeneration mode of action different from systemic/liver IGF-1.

    ReviewPMID 12023866 ↗

  5. 05

    The MGF/E-domain peptide increases myoblast and human muscle satellite-cell proliferation and fusion and inhibits terminal differentiation in vitro.

    PreclinicalMechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.PMID 21354439 ↗

  6. 06

    Recombinant human MGF increases cellular proliferation and inhibits terminal differentiation of human myoblasts in cell culture (in vitro only).

    PreclinicalPMID 18068377 ↗

  7. 07

    MGF (C24E) promotes chondrocyte proliferation, migration and matrix synthesis and delayed cartilage degeneration in cell and rabbit models (preclinical tissue-repair effect).

    PreclinicalPMID 28599103 ↗

  8. 08

    A synthetic MGF E-domain peptide inhibited cardiomyocyte apoptosis and preserved cardiac function after myocardial infarction in mice, entering cells and localizing to the nucleus independently of IGF-1R activation (preclinical only).

    PreclinicalPMID 23712705 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice